Semaglutide
A GLP-1 receptor agonist that slows gastric emptying and reduces appetite signaling, administered weekly due to a long circulating half-life.
Research status: FDA-approved for type 2 diabetes and chronic weight management, backed by large Phase 3 trial programs.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Related in Weight Loss